Role of Cytomegalovirus (CMV) Immunoglobulin in Managing Multidrug-Resistant CMV Infection in a Kidney Transplant Recipient (KIDNEY WEEK 2025) - Oct 18, 2025 - Abstract #TH-PO0926; Pres time: Nov 6, 2025; 10:00 AM - 12:00 PM; Location: Exhibit Hall, Convention Center; "He received induction with thymoglobulin and maintenance immunosuppression with tacrolimus, MMF, and prednisone. Prophylaxis included valganciclovir (VGCV) and TMP-SMX...Despite VGCV therapy and MMF reduction, viral load rebounded to 94,600 IU/mL with resistance to VGCV and cidofovir. Maribavir (MBV) was initiated, resulting in temporary improvement, but viremia rebounded to 404,000 IU/mL...Foscarnet (FOS) was started but failed to reduce viremia...At seven months, he was discharged on letermovir (LTV), but viremia rose to 40,200 IU/mL by ten months...While not curative, CMV-Ig appeared to modulate disease activity, especially when standard options were exhausted or unavailable. This case underscores the importance of adherence, timely resistance testing, and the potential role of immunotherapeutics like CMV-Ig in refractory CMV management."
Clinical • Cardiovascular • Chronic Kidney Disease • Cytomegalovirus Infection • Diabetes • Fibrosis • Gout • Hematological Disorders • Hepatology • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Leukopenia • Liver Cirrhosis • Metabolic Disorders • Rheumatology • Transplantation
|
|
Aprajita Laroia; Ananthalaxmi Vangapalli; Daranee Chewaproug; Gitana Bradauskaite; John P. Knorr; Sudhindra Pydimarri
|